Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. (CGTX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
cgtx · stock forecast · 7 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 7 Wall Street analysts in the past 3 months
Buy
7 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $1.21
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $1.27 | ↑ 5.00% |
1-day model range: $1.26–$1.28. Peak: $1.28 (+5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CGTX · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-27 | Chardan Capital | Maintains | Buy→Buy |
| 2025-12-04 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-11-21 | B. Riley Securities | Maintains | Buy→Buy |
| 2025-11-19 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-08-08 | Chardan Capital | Maintains | Buy→Buy |
| 2025-06-26 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-05-27 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-05-08 | Chardan Capital | Maintains | Buy→Buy |
| 2025-03-24 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-21 | Chardan Capital | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Cognition Therapeutics, Inc. (CGTX) stock. Of the recent 31 rating actions, 1 were upgrades and 2 were downgrades. 7 analysts currently cover CGTX.
Analyst Recommendation Trends
CGTX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$18M
↑ 325.6% YoY
Revenue Next Year
$42M
↑ 129.1% YoY
EPS This Year
$-0.32
EPS Next Year
$-0.28
↓ 14.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast CGTX EPS of $-0.32 for the current fiscal year, based on estimates from 4 analysts. The CGTX revenue forecast is $18M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CGTX stock forecast is supported by two independent data sources: analyst consensus ratings from 7 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CGTX price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The CGTX short-term stock prediction for tomorrow is $1.27 (+5.00%).
Cognition Therapeutics, Inc. trades on NASDAQ under the ticker CGTX. The CGTX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 86% of covering analysts.
Frequently asked questions
CGTX forecast · 8 questionsAccording to 7 Wall Street analysts, the average 12-month CGTX price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $1.21.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.